TABLE 4.
Different ongoing clinical trials involving the CRISPR/Cas9 system
| Cancer type | Treatment strategy | Phase | Clinical trial identifier |
|---|---|---|---|
| Bladder cancer | PD‐1 knockout T cells | I | NCT02863913 |
| B‐cell lymphoma/leukemia | CRISPR‐Cas9‐edited CAR‐T cells targeting CD19 and CD20 or CD22 | I/II | NCT03166878 |
| B‐cell lymphoma/leukemia | CRISPR‐Cas9‐edited CAR‐T cells targeting CD19 | I/II | NCT03398967 |
| Esophageal cancer | PD‐1 knockout T cells | II | NCT03081715 |
| EBV‐positive advanced stage malignancies | PD‐1 knockout EBV‐CTL | I/II | NCT03044743 |
| Hormone‐refractory prostate cancer | PD‐1 knockout T cells | I | NCT02867345 |
| HPV‐related cervical intraepithelial neoplasia | CRISPR‐Cas9‐sg HPV E6/E7 gel to disrupt HPV DNA | I | NCT03057912 |
| Non‐small cell lung cancer | PD‐1 knockout T cells | I | NCT02793856 |
| Renal cell carcinoma | PD‐1 knockout T cells | I | NCT02867332 |
Abbreviations: PD‐1, programmed cell death protein 1; NCT, national clinical trial; CAR‐T, chimeric antigen receptor‐T cell; CD, cluster of differentiation; HPV, human papillomavirus; EBV, Epstein‐bar virus; EBV‐CTL, Epstein‐bar virus‐specific cytotoxic T cell.